Zahi A Fayad, PhD
- DIRECTOR TRANSLATIONAL AND MOLECULAR IMAGING INSTITUTE
- PROFESSOR | Radiology
- PROFESSOR | Medicine, Cardiology
Research Topics:Atherosclerosis, Cardiovascular, Computed Tomography, Image Analysis, Imaging, Magnetic Resonance Imaging, Nanotechnology
Dr. Fayad serves as Professor of Radiology and Medicine (Cardiology) at the Mount Sinai School of Medicine. He is the Director of the Translational and Molecular Imaging Institute, Director and Founder of the Eva and Morris Feld Imaging Science Laboratories and Director of Cardiovascular Imaging Research at the Mount Sinai School of Medicine and Mount Sinai Medical Center. Dr. Fayad is one of the world's leaders in the development and use of multimodality cardiovascular imaging including, Cardiovascular Magnetic Resonance (CMR), computed tomography (CT), and positron emission tomography (PET), and molecular imaging to study cardiovascular disease. His recent focus has been on the noninvasive assessment of atherosclerosis (See Nature 2008; 451:953-957). He also has been developing novel methods for targeted drug delivery to improve the treatment of atherosclerosis. He holds 7 US and Worldwide patents in the field of imaging. He is currently the principal investigator of two federal grants funded by the National Institutes of Health's National Heart, Lung and Blood Institute totaling over four million dollars. He is also the principal investigator of the NIH funded General Clinical Research Center Imaging Core. Dr. Fayad has authored more than 200 peer-reviewed publications, 50 book chapters, and over 400 meeting presentations.
Dr. Fayad is past-deputy Editor of Magnetic Resonance in Medicine (MRM), immediate past-president of the Society of Atherosclerosis and Prevention (SAIP), fellow of the American Heart Association (AHA) where he is currently serving on the National Research Committee and on the Council on Cardiovascular Radiology and Intervention (CVRI). He is also a fellow of the American College of Cardiology (ACC), where he serves on the Cardiovascular Collaborative Imaging (CCI) Committee. He is member of the NIH's National Lung, and Blood Institute (NHLBI) Cardiovascular Strategic Planning Working Group on Vascular Disease and Hypertension. Dr. Fayad is on the editorial boards of the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB), Journal of Cardiovascular Magnetic Resonance, Nature Clinical Practice Cardiovascular Medicine (NCPCM), Atherosclerosis, and Journal of the American College of Cardiology Imaging (JACC Imaging). He participates regularly to the AHA/ACC writing groups. He serves on numerous study sections including those from NIH as well as the National Academy of Science. He is a member of the New York University Program in Computational Biology. He is also Visiting Scientist, Spanish National Center for Cardiovascular Research-CNIC (Fundacion Centro Nacional de Investigaciones Cardiovasculares). He is a past member of the board of trustees of the Society of Cardiovascular Magnetic Resonance (SCMR);and he is past member of the Scientific Program Committee of the International Society of Magnetic Resonance in Medicine (ISMRM).
He is the recipient of multiple prestigious awards and recently he was the given the John Paul II Medal from Krakow, Poland as a recognition for the potential his work on humankind. As a teacher and mentor, Dr. Fayad has been also extremely successful. He has trained over 30 postdoctoral fellows, clinical fellows and students. His trainees have received major awards, fellowships, and positions in academia and industry. In 2008 he received the Outstanding Teacher Award from the ISMRM for his teaching on cardiovascular imaging and molecular imaging.
In 2002 he was guest editor of the Neuroimaging Clinics on Atherosclerosis Imaging. In 2004 he co-published a comprehensive book on CMR with the publisher Martin Dunitz from the Taylor and Francis Group. In 2000, Dr. Fayad and his collaborators at Mount Sinai published the first non invasive in vivo coronary plaque images in humans and his presentations of his pioneering work received coverage in a multitude of national and international media such as the Fortune, Washington Post, USA Today, NBC Today, CBS early show, NBC News, Chicago Tribune, Washington Times, New York Magazine, El Mundo, Parade Magazine, etc. That publication was selected as American Heart Association's top 10 research advances for the year 2000. In 2003 his paper entitled 'Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging' as published in the journal CIRCULATION in August 1, 2000, has been identified by ISI to be one of the most cited papers. His current research continues to receive national and international acclaim and coverage from the scientific and general media. In 2001 he was guest Editor of Neuroimaging Clinics of North America. In 2007 he was a guest editor for a special issue of "Topics in MRI" on the subject of Atherosclerosis. In 2008 he served as a guest editor of a special issue NCPCM on Molecular Imaging and currently he is serving as guest editor for ATVB and NCPCM on special issues on cardiovascular imaging.
Dr. Fayad had his trainings at the Johns Hopkins University (Nitish Thakor, Elliott McVeight, Elias Zerhouni and William Brody) and at the University of Pennsylvania (Leon Axel). From 1996 to 1997 he was junior faculty in the Department of Radiology and the University of Pennsylvania. In 1997 he joined the faculty at Mount Sinai School of Medicine.
He is married to Monique P. Fayad, MBA and is the proud father of Chloe and Christophe, and after spending seven years in Manhattan now lives in Larchmont, NY.
Multi-Disciplinary Training AreasBiophysics and Systems Pharmacology [BSP], Clinical Research Education Program [CLR]
BSEE, Bradley University
MSE, Johns Hopkins University
PhD, University of Pennsylvania
Opening Session Distinguished Lecturer
My laboratory is focused on developing and using noninvasive imaging methods that allow the early detection, prevention, and treatment of cardiovascular disease. Despite considerable therapeutic advances over the past 50 years, cardiovascular disease is the leading cause of death worldwide. This is mainly a result of the increasing prevalence of atherosclerosis, owing to the ageing population, the improved survival of patients with atherosclerotic cardiovascular disease and, above all, the widespread under-recognition and undertreatment of individuals with risk factors for atherosclerosis. Atherosclerosis is characterized by the thickening of the arterial wall to form an atherosclerotic plaque, a process in which cholesterol deposition, inflammation, extracellular-matrix formation and thrombosis have important roles (see Sanz and Fayad Nature 2008; 45:953-957). Symptoms occur late in the course of disease and are usually caused by the narrowing of the lumen of the artery, which can happen gradually (as a result of progressive plaque growth) or suddenly (as a result of plaque rupture and, subsequently, thrombosis). The resultant decrease in blood supply can affect almost any organ, although coronary heart disease and stroke are the most common consequences.
Traditionally, diagnosis of atherosclerosis was possible only at advanced stages of disease, either by directly revealing the narrowing of the arterial lumen (stenosis) or by evaluating the effect of arterial stenosis on organ perfusion. We are developing and using, new imaging approaches that allow the assessment not only of the morphology of blood vessels but also of the composition of the vessel walls, enabling atherosclerosis-associated abnormalities in the arteries (including the coronary arteries) to be observed, down to the cellular and molecular level in some cases. Some of these approaches are now in clinical use or are being tested in clinical trials, whereas others are better suited to basic (preclinical) and translational research.
Our current activities are focused on:
Imaging Acquisition and Analysis Methods: Development of novel multimodality cardiovascular imaging and analysis techniques using macro- and micro- Cardiovascular Magnetic Resonance (CMR), computed tomography (CT), positron emission tomography (PET), and optical imaging.
Early Detection and Outcomes Prediction: Use of in vivo noninvasive multimodality imaging methods for the early detection of atherosclerosis in humans and for cardiovascular events and outcomes prediction.
Clinical Trials and Drug Development: Use in vivo noninvasive multimodality imaging methods in clinical trials for the development and testing of novel therapeutics to treat atherosclerosis.
Molecular Imaging: Development and use of novel multimodality imaging nanoparticulate systems to monitor fundamental cellular/molecular events in living subjects including patients.
Drug Delivery: Development and use of novel targeted drug delivery nanoparticulate systems to improve the treatment of atherosclerosis in living subjects including patients.
- GEMINI TF PET/MR Clinical Investigation
The purpose of this study is to establish the imaging performance of the new (first in the world) PET/MR (Positron Emission Tomography/Magnetic Resonance) imaging system. The Gemini TF PET/MR provides whole-body PET and MR imaging and is capable of running in combination...
- Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study (CIRT)
Vascular inflammation, a central feature of atherosclerosis, participates in the initiation, perpetuation and instability of plaques. Multiple clinical trials of cholesterol lowering therapy with statins have demonstrated that reductions in atherosclerotic cardiovascular disea...
- A multi-center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and effects on arterial structure and function of ACZ885 (canakinumab) in patients with clinically evident atherosclerosis and either type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT)
The purpose of this study is to look at the safety and effectiveness of an investigational drug called ACZ885 (canakinumab) when used in people with documented Type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT) with atherosclerotic vascular disease . We are in...
- A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
The purpose of this study is to look at the safety and effectiveness of an investigational drug called BMS-582949 compared to placebo (looks like the study drug but does not have any medicine in it) and atorvastatin (Lipitor™), a lipid-lowering therapy. BMS-582949 is currently...
Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008; 451(7181): 953-957.